arising from physical forces such as laser beams and to compositions containing phenyl nitrones and dihydrolipoic acids or alpha-lipoic acid as neuroprotective agents. The protective effect is believed to be due to the metabolites ability to protect neurons by a direct antioxidant effect, recycling of antioxidant vitamins E and C by redox, enhancement of glutathione, creation of at least 8 species of free radicals, and enhancement of intracellular ATP. Such may be useful in glaucoma, temporal arteritis, macular degeneration, diabetic retinopathy, proliferative retinopathy, retinitis pigmentosa, and as an adjunctive prophylactic therapy prior to or following cataract surgery.

Luz D. Ortiz,

Army Federal Register Liaison Officer. [FR Doc. 01–27865 Filed 11–5–01; 8:45 am] BILLING CODE 3710–08–M

DEPARTMENT OF DEFENSE

Department of the Army

Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Pharmaceutical Composition Containing pGLU-GLU-PRO-NH2 and Method for Treating Diseases and Injuries to the Brain, Spinal Cord and Retina Using Same

AGENCY: Army Medical Research and Materiel Command, DOD.

ACTION: Notice.

SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the availability for licensing of U.S. Patent Application No. 09/692,938 entitled "Pharmaceutical Composition Containing pGLU-GLŪ-PRO-NH2 and Method for Treating Diseases and Injuries to the Brain, Spinal Cord and Retina Using Same" and filed October 20, 2000. Foreign rights are also available (PCT/US00/29278). The United States Government, as represented by the Secretary of the Army, has rights in this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, Maryland 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619–6664. Both at telefax (301) 619–5034.

SUPPLEMENTARY INFORMATION: A

neuroprotectant composition wherein the active ingredient is pGLU–GLU–PRO–NH2 or a combination of pGLU_GLU–PRO–NH2 (EEP) and N-tert-Butyl- α -(2sulfophenyl)nitrone (SPBN) or other nitrone. A method of treating and preventing diseases and injuries of the brain, spinal cord and retina is also presented by administering the endogenous tripeptide EEP to a subject as a neuroprotectant or by administering EEP in combination with SPBN or other nitrone.

Luz D. Ortiz,

Army Federal Register Liaison Officer. [FR Doc. 01–27864 Filed 11–5–01; 8:45 am] BILLING CODE 3710–08–M

DEPARTMENT OF DEFENSE

Department of the Army

Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Treatment of and/or Prophylaxis Against Brain and Spinal Cord Injury

AGENCY: Army Medical Research and Materiel Command, DOD.

ACTION: Notice.

SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the availability for licensing of U.S. Patent Application No. 09/556,954 entitled "Treatment of and/or Prophylaxis Against Brain and Spinal Cord Injury" and filed April 21, 2000. The United States Government, as represented by the Secretary of the Army, has rights in this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, Maryland 21702–5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619–6664. Both at telefax (301) 619–5034.

supplementary information: The administration of α -lipoic acid (α -LA) and dihydrolipoic acid (DHL) both as a preventive measure before exposure to conditions which may cause damage, such as rapid changes in atmospheric pressure, and as a means of preventing or ameliorating damage arising from such injury provides benefits not currently available. The active agents

may be administered systematically or to the injured tissue. For example, when there is spinal cord injury, the active agents may be administered intrathecally.

Luz D. Ortiz,

Army Federal Register Liaison Officer. [FR Doc. 01–27866 Filed 11–5–01; 8:45 am] BILLING CODE 3710–08–M

DEPARTMENT OF DEFENSE

Department of the Army

Performance Review Boards Membership

AGENCY: Department of the Army, DoD. **ACTION:** Notice.

SUMMARY: Notice is give of the names of members of a Performance Review Board for the Department of the Army. **EFFECTIVE DATE:** December 11, 2001.

FOR FURTHER INFORMATION CONTACT: David Stokes, U.S. Army Senior Executive Service Office, Assistant Secretary of the Army, Manpower & Reserve Affairs, 111 Army, Washington,

DC 20310-0111.

SUPPLEMENTARY INFORMATION: Section 4314(c)(1) through (5) of Title 5, U.S.C., requires each agency to establish, in accordance with regulations, one or more Senior Executive Service performance review boards. The boards shall review and evaluate the initial appraisal of senior executives' performance by supervisors and make recommendations to the appointing authority or rating official relative to the performance of these executives.

The members of the Performance Review Board for the U.S. Army Corps of Engineers are:

- 1. MG Hans Van Winkle (chair).
- 2. Dr. Lewis Link (alternative chair).
- 3. BG Carl Strock.
- 4. BG Peter Madsen.
- 5. Mr. Fred Caver.
- 6. Ms. Linda Garvin.
- 7. Mr. Joe Tyler.
- 8. Mr. Rob Vining.9. Mr. Steve Browning.
- 10. Mr. Louis Carr.

Luz D. Ortiz,

Army Federal Register, Liaison Officer.
[FR Doc. 01–27868 Filed 11–5–01; 8:45 am]
BILLING CODE 3710–08–M

DEPARTMENT OF EDUCATION

National Assessment Governing Board; Meeting

AGENCY: National Assessment Governing Board, Education.